Eculizumab, sold under the brand name Soliris among others, is a recombinant humanized monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis, and neuromyelitis optica.[6][7] In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death.[9] Eculizumab was the first drug approved for each of its uses, and its approval was granted based on small trials.[10][11][12][13] It is given by intravenous infusion.[6]
Side effects include a risk for meningococcal infections and it is only prescribed to those who have enrolled in and follow a risk evaluation and mitigation strategy, which involves counseling people and ensuring that they are vaccinated.[6][14] It is a humanized monoclonal antibody functioning as a terminal complement inhibitor.[11]
It is developed, manufactured, and marketed by Alexion Pharmaceuticals.[15]: 6
^ ab"Bekemv". European Medicines Agency (EMA). 15 May 2023. Retrieved 15 May 2023.
^Cite error: The named reference Generium was invoked but never defined (see the help page).
^ ab"Epysqli EPAR". European Medicines Agency (EMA). 31 May 2023. Retrieved 31 May 2023.
^"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
^"Soliris - Summary of Product Characteristics (SmPC)". (emc). 16 July 2021. Archived from the original on 21 May 2022. Retrieved 9 April 2022.
^ abcd"Soliris- eculizumab injection, solution, concentrate". DailyMed. 20 April 2021. Archived from the original on 9 April 2022. Retrieved 9 April 2022.
^ ab"Soliris EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 19 October 2019. Retrieved 9 April 2022.
^"Epysqli". Union Register of medicinal products. 31 May 2023. Retrieved 6 June 2023.
^Martí-Carvajal AJ, Anand V, Cardona AF, Solà I (October 2014). "Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria". The Cochrane Database of Systematic Reviews. 10 (10): CD010340. doi:10.1002/14651858.CD010340.pub2. PMID 25356860.
^Cite error: The named reference FDA eculiz was invoked but never defined (see the help page).
^ abCite error: The named reference Rother2007 was invoked but never defined (see the help page).
^Cite error: The named reference Dmytrijuk2008 was invoked but never defined (see the help page).
^Keating GM (December 2013). "Eculizumab: a review of its use in atypical haemolytic uraemic syndrome". Drugs. 73 (18): 2053–2066. doi:10.1007/s40265-013-0147-7. PMID 24249647. S2CID 36682579.
^"Soliris - Summary of Product Characteristics". UK Electronic Medicines Compendium. 23 March 2017. Archived from the original on 19 February 2018. Retrieved 18 July 2017.
^Cite error: The named reference Biosimilar_2013 was invoked but never defined (see the help page).
Eculizumab, sold under the brand name Soliris among others, is a recombinant humanized monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria...
monoclonal antibody eculizumab reduces the need for blood transfusions and improves quality of life for those affected by PNH. Eculizumab dramatically alters...
symptoms with the use of eculizumab and treprostinil. Discovered by dermatopathologist, Cynthia Magro, response to eculizumab is often immediate and dramatic...
patients switching from eculizumab. The study showed that crovalimab maintained disease control in PNH patients switching from eculizumab. COMMODORE 2 is a...
activity in people who are clinically stable after having been treated with eculizumab for at least the past six months. The most common side effects are upper...
March 2024. Danicopan is indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis in adults with paroxysmal...
for example anti–factor H antibodies.: 1933 Prior to availability of eculizumab (Soliris) and ravulizumab (Ultomiris), an estimated 33–40% of patients...
specializes in orphan drugs to treat rare diseases. Its products include eculizumab (Soliris) and ravulizumab (Ultomiris), both used to treat the rare disorders...
also used in these conditions and include rituximab, basiliximab and eculizumab. Blood products including intravenous immunoglobulin and a process known...
who had not received a complement inhibitor or had previously received eculizumab. These trials demonstrated that 1–2 years of pegcetacoplan treatment effectively...
clinical condition. Kurolap and colleagues treated patients with off-label eculizumab, a humanized anti-C5 monoclonal antibody and complement inhibitor, and...
warned of an increased risk of anemia or hemolysis in people treated with eculizumab (Soliris). The highest risk was when individuals "received a dose of Soliris...
of AQP4-IgG binding), sivelestat (neutrophil elastase inhibitor), and eculizumab (complement inhibitor). There is little research into the primary causes...
"Unusual Neisseria species as a cause of infection in patients taking eculizumab". J Infect. 78 (2): 113–118. doi:10.1016/j.jinf.2018.10.015. PMC 7224403...
Global Information
(what is this?) (verify)